[1]Dewan MZ, Ahmed S, Iwasaki Y, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer[J]. Biomed Pharmacother, 2006, 60(6):273-276.
[2]Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410(6824):50-56.
[3]Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis[J]. Cancer Metastasis Rev, 2007,26(34):401-420.
[4]Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models[J]. Cancer Res, 2007,67(15):7518-7524.
[5]Teicher B A, Fricker S P. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer[J]. Clinical Cancer Res,2010,16(11):2927-2931.
[6]Wang YL,He XM, Tang W, et al. Effect of stromal cell derived factor-1α/CXCR4/CXCR7 axis on migration of the bone marrow mesenchymal stem cells[J]. Acta Anatomica Sinica, 2014,45(5):639-645.(in Chinese)
王玉兰,何晓梅,唐薇,等. 基质细胞衍生因子-1α/CXCR4/CXCR7轴对骨髓间充质干细胞迁移的影响[J]. 解剖学报,2014, 45(5):639-645.
[7] Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway[J]. Biochem Biophys Res Commun, 2007, 3 (359):716-722.
[8]Wu J, Wu X, Liang W, et al. Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis[J]. Tumour Biol, 2014, 35(4):3709-3715.
[9]Han M, Lv S, Zhang Y, et al. The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis[J]. Tumour Biol, 2014, 35(5):4589-4597.
[10]Lv S, Yang Y, Kwon S, et al. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis[J]. Histopathology,2014,64(5):701-712.
[11]Schimanski CC, Bahre R, Gockel I, et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4[J]. Br J Cancer, 2006,95(2):210-217.
[12]Billadeau DD, Chatterjee S, Bramati P, et al. Characterization of the CXCR4 signaling in pancreatic cancer cells[J]. Int J Gastrointest Cancer, 2006,37(4):110-119.
[13]Miki J, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens[J]. Cancer Res, 2007,67(7):3153-3161.
[14]Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting[J]. Drug Des Devel Ther, 2015, 9(1):4953-4964.
[15]Liang Z, Bian X, Shim H. Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression[J]. Breast Cancer Research and Treatment, 2014, 146(3):535-542.
[16]Liu R, Tan YZh, Wang HJ, et al. The effects of cytokines on the migration and mobilization of lympahatic endothelial progenitor cells[J]. Acta Anatomica Sinica, 2008, 39(1):45-49.(in Chinese)
刘锐,谭玉珍,王海杰,等. 细胞因子对淋巴管内皮祖细胞的趋化和动员作用[J]. 解剖学报,2008,39(1):45-49.
[17]Chen DP, Zhang ZhJ, Wu XL, et al. Construction of rat CXCR4 gene RNAi lentivirus vector and its expression in bone marrow mesenchymal stem cells[J]. Chinese Journal of Biotechnology, 2009, 25(2):299-305.(in Chinese)
陈东平,张志坚,吴秀丽,等. 大鼠CXCR4基因RNAi慢病毒载体的构建及其在骨髓间质干细胞中的表达[J]. 生物工程学报,2009,25(2):299-305.
[18]Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis[J]. Cancer Res,2005,65(3):967-971.
[19]Jiang K, Li J, Yin J, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy[J]. Biomaterials, 2015, 59(1):77-87.
[20]Sasaki H, Yoshida K, Hozumi A, et al. CRISPR/Cas9-mediated gene knockout in the ascidian Ciona intestinalis [J]. Dev Growth Differ, 2014, 56(7):499-510.
[21]Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells [J]. Nat Biotechnol, 2013, 31(9):822-826..
[22]Li K, Wang G, Andersen T, et al. Optimization of genome engineering approaches with the CRISPR/Cas9 system[J]. PLoS One, 2014, 9(8):e105779.
[23]Rath D, Amlinger L, Rath A, et al. The CRISPR-Cas immune system: biology, mechanisms and applications[J]. Biochimie, 2015, 117(1):119-128.
[24]Trevino AE, Zhang F. Genome editing using Cas6 nickases [J]. Methods Enzymol, 2014, 546(1):161-174.
[25]Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science, 2012, 337(6096):816-821.
|